Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial.

MLA

Hanley, Daniel F., et al. “Efficacy and Safety of Minimally Invasive Surgery with Thrombolysis in Intracerebral Haemorrhage Evacuation (MISTIE III): A Randomised, Controlled, Open-Label, Blinded Endpoint Phase 3 Trial.” Lancet (London, England), vol. 393, no. 10175, Mar. 2019, pp. 1021–32. EBSCOhost, https://doi.org/10.1016/S0140-6736(19)30195-3.

APA

Hanley, D. F., Thompson, R. E., Rosenblum, M., Yenokyan, G., Lane, K., McBee, N., Mayo, S. W., Bistran-Hall, A. J., Gandhi, D., Mould, W. A., Ullman, N., Ali, H., Carhuapoma, J. R., Kase, C. S., Lees, K. R., Dawson, J., Wilson, A., Betz, J. F., Sugar, E. A., … Awad, I. A. (2019). Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. Lancet (London, England), 393(10175), 1021–1032. https://doi.org/10.1016/S0140-6736(19)30195-3

Chicago

Hanley, Daniel F, Richard E Thompson, Michael Rosenblum, Gayane Yenokyan, Karen Lane, Nichol McBee, Steven W Mayo, et al. 2019. “Efficacy and Safety of Minimally Invasive Surgery with Thrombolysis in Intracerebral Haemorrhage Evacuation (MISTIE III): A Randomised, Controlled, Open-Label, Blinded Endpoint Phase 3 Trial.” Lancet (London, England) 393 (10175): 1021–32. doi:10.1016/S0140-6736(19)30195-3.